Get to know our clinical trials

Study to evaluate the efficacy and safety of treatment combinations based on multiple immunotherapies in patients with metastatic non-small cell lung carcinoma.

THE PURPOSE IS TO EVALUATE THE DRUG ATEZOLIZUMAB (ITA) IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN (CHEMOTHERAPY) TO FIND OUT WHAT EFFECTS THIS TREATMENT HAS, WHETHER GOOD OR BAD, ON YOU AND YOUR LUNG CANCER.

Navarre headquarters
Madrid headquarters
Diseases
Cáncer de pulmón
Inmunoterapia, vacunas contra el cáncer
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • UNBLINDED, MULTICENTER, RANDOMIZED, PHASE IB/II UMBRELLA STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS BASED ON MULTIPLE IMMUNOTHERAPIES IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CARCINOMA (PULMONARY MORPHEUS).
  • Code EudraCT: 2017-001267-21
  • Protocol number: BO39610
  • Promoter: Roche Farma, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.